Stoke Therapeutics (NASDAQ:STOK) Receives “Buy” Rating from Needham & Company LLC
Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $22.00 price objective on the stock. Needham & Company LLC’s price objective suggests a potential upside of 237.42% from […]
Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $22.00 price objective on the stock. Needham & Company LLC’s price objective suggests a potential upside of 237.42% from […]